Although the majority of melanomas are characterized by a clonal mutation in either BRAF or NRAS, likely limiting the added clinical value of mFast‐SeqS in patients with melanoma, we demonstrated that ddPCR showed a high correlation with mFast‐SeqS. This evidence concerns the gene NRAS and melanoma.